Editorial
The importance of RET-directed therapy in patients with RET- rearranged non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 7)
:S1121-S1123
.
(24 October 2017)
Mitochondrial calcium: a crucial hub for cancer cell metabolism?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1124-S1127
.
(24 October 2017)
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy
Translational Cancer Research
2017;
6
(Suppl 7)
:S1128-S1131
.
(24 October 2017)
Immunotherapy in endometrial cancer: who are the most appropriate patients?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1132-S1135
.
(24 October 2017)
The future of prostate cancer precision medicine: anti-ERG therapies
Translational Cancer Research
2017;
6
(Suppl 7)
:S1136-S1138
.
(24 October 2017)
BCL9L and caspase-2—new guardians against aneuploidy
Translational Cancer Research
2017;
6
(Suppl 7)
:S1139-S1142
.
(24 October 2017)
Mighty RapaLink-1 vanquishes undruggable mutant mTOR in glioblastoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1143-S1148
.
(24 October 2017)
Mixing, matching and modifying the prostate cancer microenvironment
Translational Cancer Research
2017;
6
(Suppl 7)
:S1149-S1152
.
(24 October 2017)
Auto-antibodies against P53—a useful complementary biomarker for ovarian cancer screening?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1153-S1157
.
(24 October 2017)
“Wonder drugs” in central nervous system lymphoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1158-S1162
.
(24 October 2017)
Fucosyltransferase 8 as a driver of melanoma metastasis: a new target for melanoma therapy?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1163-S1165
.
(24 October 2017)
Morphine, when used for treating patients with acute pancreatitis, could be more risky than previously suspected
Translational Cancer Research
2017;
6
(Suppl 7)
:S1166-S1168
.
(24 October 2017)
About rearranged during transfection in non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 7)
:S1169-S1172
.
(24 October 2017)
Brigatinib, a new treatment option in ALK-rearranged advanced non-small cell lung carcinoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1173-S1176
.
(24 October 2017)
Targeted therapies of HER2-positive gastric adenocarcinoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1177-S1180
.
(24 October 2017)
Liquid biopsies: envisioning a future when tissue is avoidable in lung cancer treatment decision-making
Translational Cancer Research
2017;
6
(Suppl 7)
:S1181-S1186
.
(24 October 2017)
Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 7)
:S1187-S1190
.
(24 October 2017)
Notch signalling: the true driver of small cell lung cancer?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1191-S1196
.
(24 October 2017)
Targeting glioblastoma stem-cells: a recurrent challenge in neurooncology
Translational Cancer Research
2017;
6
(Suppl 7)
:S1197-S1199
.
(24 October 2017)
Stereotactic conformal radiation therapy in the treatment of benign and low-grade brain tumors
Translational Cancer Research
2017;
6
(Suppl 7)
:S1200-S1204
.
(24 October 2017)
Targeting miR-155 in FLT3-ITD mutated AML: ready for prime time?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1205-S1207
.
(24 October 2017)
Editorial on the use of immunotherapy in renal-cell carcinoma—promising results in combination therapy with ipilimumab and nivolumab
Translational Cancer Research
2017;
6
(Suppl 7)
:S1208-S1211
.
(24 October 2017)
Racial disparities in management of hepatocellular carcinoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1212-S1214
.
(24 October 2017)
Finding a place for ceritinib in the landscape of ALK-positive nonsmall cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 7)
:S1215-S1218
.
(24 October 2017)
Lipid transactions in cancer—the fat addiction and glycerol-3-phosphate acyltransferase action
Translational Cancer Research
2017;
6
(Suppl 7)
:S1219-S1224
.
(24 October 2017)
Nivolumab for chemorefractory oesophageal squamous cell carcinoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1225-S1228
.
(24 October 2017)
Advanced esophagogastric cancers: the making or breaking of a backbone
Translational Cancer Research
2017;
6
(Suppl 7)
:S1229-S1233
.
(24 October 2017)
Microphthalmia-associated transcription factors activate mTORC1 through RagD GTPase gene expression
Translational Cancer Research
2017;
6
(Suppl 7)
:S1234-S1238
.
(24 October 2017)
ONC201: a new treatment option being tested clinically for recurrent glioblastoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1239-S1243
.
(24 October 2017)
When better still might not be good enough
Translational Cancer Research
2017;
6
(Suppl 7)
:S1244-S1247
.
(24 October 2017)
Optimal local therapy for early-stage small cell lung cancer: surgery needs a seat at the table
Translational Cancer Research
2017;
6
(Suppl 7)
:S1248-S1252
.
(24 October 2017)
IDH mutational status and the immune system in gliomas: a tale of two tumors?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1253-S1256
.
(24 October 2017)
Cancer relevance of signal recognition particle RNA and other non-coding RNAs in extracellular vesicles
Translational Cancer Research
2017;
6
(Suppl 7)
:S1257-S1260
.
(24 October 2017)
Monitoring response to therapy by testing circulating tumor DNA in urine
Translational Cancer Research
2017;
6
(Suppl 7)
:S1261-S1263
.
(24 October 2017)
Switching gear and looking from a different angle in the treatment of HER2-positive disease
Translational Cancer Research
2017;
6
(Suppl 7)
:S1264-S1268
.
(24 October 2017)
Outcomes in BRCA mutation carriers: evaluation of current data for optimal clinical care
Translational Cancer Research
2017;
6
(Suppl 7)
:S1269-S1272
.
(24 October 2017)
Identifying drivers of metastasis; towards a systematic approach
Translational Cancer Research
2017;
6
(Suppl 7)
:S1273-S1276
.
(24 October 2017)
Targeting sphingosine kinase 1 localization as novel target for ovarian cancer therapy
Translational Cancer Research
2017;
6
(Suppl 7)
:S1277-S1280
.
(24 October 2017)
Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
Translational Cancer Research
2017;
6
(Suppl 7)
:S1281-S1284
.
(24 October 2017)
Combining loco-regional treatments in early hepatocellular carcinoma: new achievements overcoming old limitations
Translational Cancer Research
2017;
6
(Suppl 7)
:S1285-S1287
.
(24 October 2017)
The optimal threshold for α-fetoprotein and vitamin K absence or antagonist-II is still an open issue
Translational Cancer Research
2017;
6
(Suppl 7)
:S1288-S1290
.
(24 October 2017)
Letter to the Editor
Imaging of T cells in patients with recurrent glioblastoma
Translational Cancer Research
2017;
6
(Suppl 7)
:S1291-S1292
.
(24 October 2017)
Survival benefit of TACE combined with sorafenib for hepatocellular carcinoma patients with portal vein tumor thrombus
Translational Cancer Research
2017;
6
(Suppl 7)
:S1293-S1295
.
(24 October 2017)
Infusion-related reactions with administration of avelumab: mild and manageable side effects
Translational Cancer Research
2017;
6
(Suppl 7)
:S1296-S1298
.
(24 October 2017)
Patterns of failure in head and neck cancer patients treated with intensity modulated radiation therapy: editorial response
Translational Cancer Research
2017;
6
(Suppl 7)
:S1299-S1300
.
(24 October 2017)
Disclosure:
This supplement was published without any sponsorship or funding.
